25 July 2013  
EMA/631299/2013  
Human Medicines Development and Evaluation 
Statement indicating compliance with the agreed completed 
paediatric investigation plan  
Medicinal product  
Prezista 
Darunavir 
Pharmaceutical forms: 
See Annex A of the CHMP Opinion 
Strengths: 
See Annex A 
Route of administration: 
See Annex A 
Packaging and package sizes: 
See Annex A 
Numbersin the Community 
See Annex A 
Register of Medicinal Products: 
Marketing Authorisation Holder (MAH): 
Name and address of the MAH: 
Janssen-Cilag International N.V. 
Turnhoutseweg 30 
B-2340 Beerse 
BELGIUM 
Procedure  
Procedure number: 
EMEA/H/C/000707/II/0054 
Further to the compliance check performed under Article 23 of Regulation (EC) No 1901/2006, and in 
accordance with Article 28(3) and Article 45(3) of the said Regulation it is concluded that: 
-  the development of this product has complied with all measures in the agreed paediatric investigation 
plan P/138/2010. For the purpose of the application of Article 45(3) of Regulation (EC) No 1901/2006, 
all studies in the agreed paediatric investigation plan P/138/2010 were completed after the entry into 
force of that Regulation, 
-  the Summary of Product Characteristics reflects the results of studies conducted in compliance with 
this agreed paediatric investigation plan.  
7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom 
Telephone  +44 (0)20 7418 8400  Facsimile +44 (0)20 7523 7455  
E-mail  info@ema.europa.eu  Website  www.ema.europa.eu 
An agency of the European Union   
© European Medicines Agency, 2013. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
 
  
 
  
 
 
 
 
